In vivo near-infrared fluorescence imaging of integrin α vβ3 in brain tumor xenografts

Cancer Research

Volumn 64, Issue 21, 2004, Pages 8009-8014

  Chen, Xiaoyuan ^a,b   Conti, Peter S ^a   Moats, Rex A ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CONTRAST MEDIUM; FLUORESCENT DYE; INTEGRIN RECEPTOR; LYMPHOCYTE ANTIGEN; VITRONECTIN RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; INFRARED RADIATION; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CARBOCYANINES; CELL LINE, TUMOR; FEMALE; FLUORESCENCE; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 7444235966     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1956     Document Type: Article

References (36)

1. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90:561-5.
2. 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003;6:105-19.
3. Hodivala-Dilke KM, Reynolds AR, Reynolds LE. Integrins in angiogenesis: multi-talented molecules in a balancing act. Cell Tissue Res 2003;314:131-44.
4. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med 2003;3:659-71.
5. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003;20:203-213.
6. 3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4:2625-34.
7. 3 expression in colon carcinoma correlates with survival. Mod Pathol 2001;14:1126-32.
8. 5 integrin expression in glioma periphery. Neurosurgery 2001;49:380-9.
9. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2:703-16.
10. Hamm CW. Ami-integrin therapy. Annu Rev Med 2003;54:425-35.
11. 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003;4:123-31.
12. 3. Q J Nucl Med 2003;47:209-20.
13. Haubner RH, Wester HJ, Weber WA, Schwaiger M. Radiotracer-based strategies to image angiogenesis. Q J Nucl Med 2003;47:189-99.
14. 64Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41-9.
15. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004;31:179-89.
16. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15:61-9.
17. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
18. 3 integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-1.
19. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002;17:641-6.
20. Becker A, Hessenius C, Licha K, et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 2001;19:327-33.
21. Ballou B, Fisher GW, Deng JS, Hakala TR, Srivastava M, Farkas DL. Cyanine fluorochrome-labeled antibodies in vivo: assessment of tumor imaging using Cy3, Cy5, Cy5.5, and Cy7. Cancer Detect Prev 1998;22:251-7.
22. Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999;17:375-8.
23. Ke S, Wen X, Gurfinkel M, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003;63:7870-5.
24. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A Jr. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 2003;63:1936-42.
25. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004;31:11-19.
26. 3 receptor. J Pharmacol Exp Ther 1997;283:843-53.
27. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219:316-33.
28. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003;17:545-80.
29. Blasberg RG, Gelovani J. Molecular-genetic imaging: a nuclear medicine-based perspective. Mol Imaging 2002;1:280-300.
30. Choy G, Choyke P, Libutti SK. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging 2003;2:303-12.
31. Buschmann V, Weston KD, Sauer M. Spectroscopic study and evaluation of red-absorbing fluorescent dyes. Bioconjug Chem 2003;14:195-204.
32. 3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004;45:1390-7.
33. Zaheer A, Lenkinski RE, Mahmood A, Jones AG, Cantley LC, Frangioni JV. In vivo near-infrared fluorescence imaging of osteoblastic activity. Nat Biotechnol 2001;19:1148-54.
34. Quaresima V, Matcher SJ, Ferrari M. Identification and quantification of intrinsic optical contrast for near-infrared mammography. Photochem Photobiol 1998;67:4-14.
35. Ntziachristos V, Bremer C, Graves EE, Ripoll J, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003;13:195-208.
36. Licha K, Riefke B, Ntziachristos V, Becker A, Chance B, Semmler W. Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. Photochem Photobiol 2000;72:392-8.